Abstract
Epilepsy is among the most common serious disabling disorders of the brain, and the global burden of epilepsy exerts a tremendous cost to society. Most people with epilepsy have acquired forms of the disorder, and the development of antiepileptogenic interventions could potentially prevent or cure epilepsy in many of them. However, the discovery of potential antiepileptogenic treatments and clinical validation would require a means to identify populations of patients at very high risk for epilepsy after a potential epileptogenic insult, to know when to treat and to document prevention or cure. A fundamental challenge in discovering biomarkers of epileptogenesis is that this process is likely multifactorial and crosses multiple modalities. Investigators must have access to a large number of high quality, well-curated data points and study subjects for biomarker signals to be detectable above the noise inherent in complex phenomena, such as epileptogenesis, traumatic brain injury (TBI), and conditions of data collection. Additionally, data generating and collecting sites are spread worldwide among different laboratories, clinical sites, heterogeneous data types, formats, and across multi-center preclinical trials. Before the data can even be analyzed, these data must be standardized. The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) is a multi-center project with the overarching goal that epileptogenesis after TBI can be prevented with specific treatments. The identification of relevant biomarkers and performance of rigorous preclinical trials will permit the future design and performance of economically feasible full-scale clinical trials of antiepileptogenic therapies. We have been analyzing human data collected from UCLA and rat data collected from the University of Eastern Finland, both centers collecting data for EpiBioS4Rx, to identify biomarkers of epileptogenesis. Big data techniques and rigorous analysis are brought to longitudinal data collected from humans and an animal model of TBI, epilepsy, and their interaction. The prolonged continuous data streams of intracranial, cortical surface, and scalp EEG from humans and an animal model of epilepsy span months. By applying our innovative mathematical tools via supervised and unsupervised learning methods, we are able to subject a robust dataset to recently pioneered data analysis tools and visualize multivariable interactions with novel graphical methods.
Highlights
The goal of the Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) is to identify relevant biomarkers of epileptogenesis after traumatic brain injury (TBI) and perform rigorous preclinical trials that permit the future design and performance of economically feasible full-scale clinical trials of antiepileptogenic therapies
Study population We present some analysis performed on human data, focusing on paravascular spaces (PVS)’ role as a potential biomarker of epileptogenesis after TBI; we analyzed clinical data and Magnetic Resonance Imaging (MRI) scans in a sample of 15 patients (12 males, 3 females, age range: 7–68 years old)
We evaluated the total number of PVSs in TBI patients and healthy controls: the average was 77 ± 48 in the first group, and 80 ± 15 in the latter
Summary
The goal of the Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) is to identify relevant biomarkers of epileptogenesis after traumatic brain injury (TBI) and perform rigorous preclinical trials that permit the future design and performance of economically feasible full-scale clinical trials of antiepileptogenic therapies. We have been developing innovative analytic tools to be shared with the broader epilepsy research community so that others may use our tools in addition to their own tools to advance research in this field By working on this difficult problem collaboratively among researchers who possess different areas of expertise, we expect to identify several biomarkers of post-traumatic epileptogenesis from the multimodal data collected as part of EpiBioS4Rx and validate those biomarkers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.